Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for treating a patient exhibiting a symptom of autistic disorder ~~or pervasive development disorder~~ comprising the step of stimulating secretion of pancreatic juices in said patient.

2. (Previously Presented) The method of claim 1 wherein the step of stimulating secretion of pancreatic juices comprises the step of administering to said patient an amount of secretin effective to stimulate secretion of the pancreatic juices.

3. (Original) The method of claim 2 wherein said effective amount of secretin is administered by infusion.

4. (Currently Amended) The method of claim 3 wherein administering said effective amount of secretin by infusion includes the step of intravenously infusing secretin in an amount of about 2 clinical units (CU) [[re]] per kilogram (kg) of body weight.

5. (Original) The method of claim 2 wherein said effective amount of secretin is administered transdermally.

6. (Previously Presented) The method of claim 5 wherein administering said effective amount of secretin transdermally includes the steps of:

applying a transdermal carrier to a portion of the skin of said patient; and

applying crystalline secretin in said effective amount onto said transdermal carrier.

7. (Previously Presented) The method of claim 6 wherein said transdermal carrier includes dimethyl sulfoxide (DMSO).

8. (Original) The method of claim 6 wherein said effective amount of secretin includes between 5 and 20 clinical units (CU) of crystalline secretin per dose.

9. (Previously Presented) The method of claim 6 wherein said transdermal carrier is selected from the group consisting of a gel and a lotion.

10. (Original) The method of claim 5 wherein administering secretin transdermally includes administering said effective amount of secretin with a patch to be applied to a portion of the skin of said patient.

11. (Canceled)

12. (Original) The method of claim 2 wherein said effective amount of secretin is administered orally.

13. (Original) The method of claim 12 wherein said effective amount of secretin is administered orally using an oral carrier selected from the group consisting of a tablet, capsule or lozenge.

14. (Original) The method of claim 2 wherein said effective amount of secretin is administered using a suppository.

15. (Original) The method of claim 2 wherein said effective amount of secretin is administered by inhalation.

16. (Previously Presented) The method of claim 2 wherein said patient suffers from autistic disorder or pervasive development disorder.

17. (Previously Presented) The method of claim 2 wherein said effective amount of secretin includes an amount of secretin sufficient to increase serotonin levels in the brain of said patient to a level effective to stimulate secretion of the pancreatic juices.

18. (Previously Presented) The method of claim 1 wherein stimulating secretion of said pancreatic juices increases at least one neuropeptide hormone selected from the group consisting of serotonin, dopamine and CCK levels in said patient.

19. (Canceled)

20. (Canceled)

21-29. (Withdrawn)

30. (Original) A method for the treatment of autism comprising the step of administering to said patient an effective amount of secretin.

31. (Original) The method of claim 30 wherein said effective amount of secretin is administered by infusion.

32. (Original) The method of claim 31 wherein administering said effective amount of secretin by infusion includes the step of intravenously transfusing secretin in an amount of about 2 clinical units (CU) per kilogram (kg) of body weight per dose.

33. (Original) The method of claim 30 wherein said effective amount of secretin is administered transdermally.

34. (Previously Presented) The method of claim 33 wherein administering said effective amount of secretin transdermally includes the steps of

applying a transdermal carrier to a portion of the skin of said patient; and

applying crystalline secretin in said effective amount onto said transdermal carrier.

35. (Previously Presented) The method of claim 34 wherein said transdermal carrier includes dimethyl sulfoxide (DMSO).

36. (Original) The method of claim 35 wherein said effective amount of secretin includes about 15 clinical units (CU) of crystalline secretin per dose.

37-39. (Cancelled)